An experimental breast cancer drug is showing promise in fighting triple negative breast cancer, a particularly aggressive form of the disease that’s hard to treat. 15% of all breast cancers are of the triple negative type. The drug, known as “BSI-201” for now, is proving effective. Up until now, drugs such as Herceptin or hormone therapy had little effect against triple negative breast cancer. Oncologists are calling BSI-201 “the most exciting potential treatment in a long time”. Currently, the drug is being tested in a major clinical trial.